• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Paragon 28 Inc.

    4/21/25 4:19:30 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email
    POS AM 1 posam.htm POST-EFFECTIVE AMENDMENT NO. 1

    As filed with the U.S. Securities and Exchange Commission on April 21, 2025
    Registration No. 333-268082
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-3 REGISTRATION STATEMENT NO. 333-268082
    UNDER THE SECURITIES ACT OF 1933
     


    Paragon 28, Inc.
    (Exact name of registrant as specified in its charter)
     


    Delaware
     
    27-3170186
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification Number)



    345 East Main Street
    Warsaw, IN 46580
    (574) 373-3333
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     


    Chad F. Phipps
    Senior Vice President,
    General Counsel and Secretary
    Zimmer Biomet Holdings, Inc.
    345 East Main Street
    Warsaw, Indiana 46580
    (574) 373-3333
    (Name and address, including zip code, and telephone number, including area code, of agent for service)
     


    Copy to:

    Gabrielle M. Witt
    Joseph E. Gilligan

    Hogan Lovells US LLP
    555 13th Street NW
    Washington, DC 20004
    (202) 637-5600
     


    Approximate date of commencement of proposed sale to the public: Not applicable

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box:  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box:  ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
     
    Large accelerated filer
     
    ☐
      
    Accelerated filer
     
    ☒
    Non-accelerated filer
     
    ☐
      
    Smaller reporting company
     
    ☐
     
     
     
      
    Emerging growth company
     
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     




    EXPLANATORY NOTE/DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the following Registration Statement on Form S-3 (the “Registration Statement”) filed by Paragon 28, Inc., a Delaware corporation (the “Registrant”), with the Securities and Exchange Commission (the “SEC”):
     
     
    ●
    Registration Statement on Form S-3 (No. 333-268082), filed with the SEC on November 1, 2022, which registered, in a primary offering, an indeterminate number or amount of securities which together could have an aggregate initial offering price not to exceed $100,000,000, and 10,000,000 shares of common stock, par value $0.01 per share, of the Registrant that the selling stockholders to be named in a supplement to the prospectus may offer for resale from time to time pursuant to the Registration Statement.

    On April 21, 2025, pursuant to the Agreement and Plan of Merger, dated as of January 28, 2025, by and among the Registrant, Zimmer, Inc. (“Zimmer”), a Delaware corporation and a wholly owned subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), Gazelle Merger Sub I, Inc., a Delaware corporation and a wholly owned Subsidiary of Zimmer (“Merger Sub”) and, for certain provisions therein, Zimmer Biomet, Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant surviving the Merger as a wholly owned subsidiary of Zimmer.

    As a result of the Merger, the Registrant has terminated all offerings of securities pursuant to the Registration Statement. Accordingly, the Registrant, by filing this Post-Effective Amendment, hereby terminates the effectiveness of the Registration Statement and, in accordance with undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities that had been registered but remained unsold at the termination of the offering, removes from registration any and all securities of the Registrant registered but unsold under the Registration Statement as of the date hereof.


    SIGNATURE

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement described above to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warsaw, State of Indiana, on April 21, 2025.

      PARAGON 28, INC.
     
           
           

    By:
    /s/ Chad F. Phipps  
        Name: Chad F. Phipps
     
        Title: Senior Vice President and Secretary
     


    No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance on Rule 478 of the Securities Act of 1933, as amended.
    Get the next $FNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

      2/6/25 6:30:00 AM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

      11/12/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

      Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

      10/17/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Paragon 28 Inc.

      SC 13G - Paragon 28, Inc. (0001531978) (Subject)

      8/9/24 9:02:32 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/14/24 3:29:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/13/24 4:23:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

      3/24/25 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

      3/11/25 4:01:00 PM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

      3/7/25 4:32:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      3/18/24 5:34:02 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      11/13/23 8:00:07 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 downgraded by Needham

      Needham downgraded Paragon 28 from Buy to Hold

      1/29/25 2:02:26 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 downgraded by William Blair

      William Blair downgraded Paragon 28 from Outperform to Mkt Perform

      1/29/25 7:36:30 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • William Blair initiated coverage on Paragon 28

      William Blair initiated coverage of Paragon 28 with a rating of Outperform

      9/29/23 7:20:32 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:07 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:10 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:14 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:24:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:23:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:22:43 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Appointment of Stephen M. Deitsch as new Chief Financial Officer

      OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

      4/4/24 11:43:23 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

      3/28/22 4:02:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care